Lutroo Imaging develops Radiocaine TM, a PET imaging radioisotope designed to objectively locate and measure pain sources by binding to sodium channels in pain-transmitting nerves. This technology aims to provide clinicians with accurate diagnostic data, improving pain management efficacy and streamlining clinical trials for new pain therapies. By enabling precise pain localization, the platform seeks to reduce reliance on subjective patient reporting and inefficient diagnostic pathways.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diagnosing chronic pain rely on subjective patient reports and behavioral observations, leading to inaccurate diagnoses and ineffective treatment. Existing diagnostic imaging techniques like MRI and CT scans often fail to identify the specific source of pain or objectively measure its intensity. This results in prolonged suffering for patients and significant economic burden due to ineffective treatments and repeated diagnostic procedures.
Solution
Lutroo Imaging is developing Radiocaine, a PET imaging radioisotope designed to visualize and quantify pain. Radiocaine binds to sodium channels in pain-transmitting nerves, allowing clinicians to locate the source of pain and measure its intensity using standard PET scanners. By providing an objective measure of pain, Radiocaine aims to improve the accuracy of diagnoses, enable more effective pain management strategies, and support the development of new pain therapies. A Radiocaine PET scan can potentially identify the pain source in under an hour, facilitating faster and more appropriate treatment.
Target Audience
The primary target audience includes radiologists, pain management specialists, neurologists, and clinical researchers focused on chronic pain diagnosis and treatment.
Features
- PET imaging radioisotope (18F) that binds to sodium channels in pain-transmitting nerves
- Visualization of pain generators through standard PET imaging
- Objective measurement of pain intensity, reducing reliance on subjective patient reports
- Potential to identify pain sources not detectable by MRI or CT scans
- Facilitates accurate diagnosis and targeted pain management strategies
- Supports clinical trials for new pain therapies by providing an objective outcome measure